CN111643517B - 桑葚多糖衍生物s-mfp-30在制备抗肿瘤药物中的应用 - Google Patents
桑葚多糖衍生物s-mfp-30在制备抗肿瘤药物中的应用 Download PDFInfo
- Publication number
- CN111643517B CN111643517B CN202010338159.XA CN202010338159A CN111643517B CN 111643517 B CN111643517 B CN 111643517B CN 202010338159 A CN202010338159 A CN 202010338159A CN 111643517 B CN111643517 B CN 111643517B
- Authority
- CN
- China
- Prior art keywords
- mfp
- mulberry
- mulberry polysaccharide
- polysaccharide derivative
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000004676 glycans Chemical class 0.000 title claims abstract description 245
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 245
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 245
- 235000008708 Morus alba Nutrition 0.000 title claims abstract description 233
- 240000000249 Morus alba Species 0.000 title claims abstract description 218
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 239000002246 antineoplastic agent Substances 0.000 title abstract description 7
- 229940041181 antineoplastic drug Drugs 0.000 title abstract description 7
- 241000218231 Moraceae Species 0.000 claims abstract description 15
- 239000000284 extract Substances 0.000 claims abstract description 13
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 11
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 11
- 206010033128 Ovarian cancer Diseases 0.000 claims abstract description 11
- 206010061535 Ovarian neoplasm Diseases 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 11
- 206010017758 gastric cancer Diseases 0.000 claims abstract description 10
- 208000005718 Stomach Neoplasms Diseases 0.000 claims abstract description 9
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims abstract description 9
- 201000011549 stomach cancer Diseases 0.000 claims abstract description 9
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims abstract description 9
- 201000007270 liver cancer Diseases 0.000 claims abstract description 8
- 208000014018 liver neoplasm Diseases 0.000 claims abstract description 8
- 229940079593 drug Drugs 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 69
- 238000000034 method Methods 0.000 claims description 61
- 239000007788 liquid Substances 0.000 claims description 26
- 235000019441 ethanol Nutrition 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 239000006228 supernatant Substances 0.000 claims description 20
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 15
- 239000012153 distilled water Substances 0.000 claims description 14
- 238000005238 degreasing Methods 0.000 claims description 12
- 239000002244 precipitate Substances 0.000 claims description 12
- 229920002678 cellulose Polymers 0.000 claims description 10
- 239000001913 cellulose Substances 0.000 claims description 10
- 238000003809 water extraction Methods 0.000 claims description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 238000001556 precipitation Methods 0.000 claims description 9
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 8
- 239000000706 filtrate Substances 0.000 claims description 8
- 238000009777 vacuum freeze-drying Methods 0.000 claims description 8
- 230000002829 reductive effect Effects 0.000 claims description 7
- 230000019635 sulfation Effects 0.000 claims description 7
- 238000005670 sulfation reaction Methods 0.000 claims description 7
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 6
- 238000000944 Soxhlet extraction Methods 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- 238000004440 column chromatography Methods 0.000 claims description 6
- 239000003480 eluent Substances 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 239000000049 pigment Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 5
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims description 4
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims description 4
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- 150000002772 monosaccharides Chemical class 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 3
- 238000010521 absorption reaction Methods 0.000 claims description 3
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 3
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 3
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- 238000005259 measurement Methods 0.000 claims description 3
- 230000004048 modification Effects 0.000 claims description 3
- 238000012986 modification Methods 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 239000003208 petroleum Substances 0.000 claims description 3
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 claims description 3
- 230000001376 precipitating effect Effects 0.000 claims description 3
- 239000008399 tap water Substances 0.000 claims description 3
- 235000020679 tap water Nutrition 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 239000002699 waste material Substances 0.000 claims description 3
- 208000003170 Bronchiolo-Alveolar Adenocarcinoma Diseases 0.000 claims description 2
- 206010058354 Bronchioloalveolar carcinoma Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 238000010828 elution Methods 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 208000016992 lung adenocarcinoma in situ Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 72
- 230000000694 effects Effects 0.000 abstract description 60
- 210000004881 tumor cell Anatomy 0.000 abstract description 27
- 241000196324 Embryophyta Species 0.000 abstract description 15
- 230000035755 proliferation Effects 0.000 abstract description 13
- 230000005012 migration Effects 0.000 abstract description 12
- 238000013508 migration Methods 0.000 abstract description 12
- 238000011161 development Methods 0.000 abstract description 7
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract description 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract description 6
- 201000002528 pancreatic cancer Diseases 0.000 abstract description 6
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract description 6
- 239000002994 raw material Substances 0.000 abstract description 5
- 231100000053 low toxicity Toxicity 0.000 abstract description 4
- 235000013376 functional food Nutrition 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 154
- 230000005764 inhibitory process Effects 0.000 description 80
- 230000004663 cell proliferation Effects 0.000 description 41
- 238000011160 research Methods 0.000 description 28
- 230000012292 cell migration Effects 0.000 description 26
- 238000002474 experimental method Methods 0.000 description 22
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 17
- 230000032683 aging Effects 0.000 description 13
- 238000000338 in vitro Methods 0.000 description 13
- 238000004113 cell culture Methods 0.000 description 12
- 230000037230 mobility Effects 0.000 description 12
- 230000000259 anti-tumor effect Effects 0.000 description 11
- 239000006143 cell culture medium Substances 0.000 description 11
- 230000036962 time dependent Effects 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 230000001550 time effect Effects 0.000 description 8
- 229910002092 carbon dioxide Inorganic materials 0.000 description 7
- 239000006285 cell suspension Substances 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 230000003698 anagen phase Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000007365 immunoregulation Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 238000005138 cryopreservation Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 230000002035 prolonged effect Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000006748 scratching Methods 0.000 description 4
- 230000002393 scratching effect Effects 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 3
- 229920001277 pectin Polymers 0.000 description 3
- 239000001814 pectin Substances 0.000 description 3
- 235000010987 pectin Nutrition 0.000 description 3
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 3
- 238000012827 research and development Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000004017 serum-free culture medium Substances 0.000 description 3
- 230000002123 temporal effect Effects 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 241000512259 Ascophyllum nodosum Species 0.000 description 2
- 244000234623 Coprinus comatus Species 0.000 description 2
- 235000004439 Coprinus comatus Nutrition 0.000 description 2
- 240000006499 Flammulina velutipes Species 0.000 description 2
- 235000016640 Flammulina velutipes Nutrition 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 235000008081 Rheum officinale Nutrition 0.000 description 2
- 241000976858 Rheum tanguticum Species 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- BBFQZRXNYIEMAW-UHFFFAOYSA-N aristolochic acid I Chemical class C1=C([N+]([O-])=O)C2=C(C(O)=O)C=C3OCOC3=C2C2=C1C(OC)=CC=C2 BBFQZRXNYIEMAW-UHFFFAOYSA-N 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000000824 cytostatic agent Substances 0.000 description 2
- 230000001085 cytostatic effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 230000005918 in vitro anti-tumor Effects 0.000 description 2
- 150000002611 lead compounds Chemical class 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 239000007758 minimum essential medium Substances 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- OAVCWZUKQIEFGG-UHFFFAOYSA-O 2-(5-methyl-2H-tetrazol-1-ium-1-yl)-1,3-thiazole Chemical compound CC1=NN=N[NH+]1C1=NC=CS1 OAVCWZUKQIEFGG-UHFFFAOYSA-O 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- 240000004507 Abelmoschus esculentus Species 0.000 description 1
- 241000726094 Aristolochia Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- 235000002568 Capsicum frutescens Nutrition 0.000 description 1
- 241000195628 Chlorophyta Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 229920000855 Fucoidan Polymers 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- 239000004940 MPF-50 Substances 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- YXOLAZRVSSWPPT-UHFFFAOYSA-N Morin Chemical compound OC1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 YXOLAZRVSSWPPT-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 244000248825 Peltandra virginica Species 0.000 description 1
- 235000001188 Peltandra virginica Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- 241001522129 Pinellia Species 0.000 description 1
- 241001080798 Polygala tenuifolia Species 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 241000206572 Rhodophyta Species 0.000 description 1
- 241000195474 Sargassum Species 0.000 description 1
- 241001558929 Sclerotium <basidiomycota> Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 241000158200 Ulva fasciata Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002579 anti-swelling effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 239000001728 capsicum frutescens Substances 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 239000009194 citrus pectin Substances 0.000 description 1
- 229940040387 citrus pectin Drugs 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 235000001705 insufficient nutrition Nutrition 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 235000007708 morin Nutrition 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008621 organismal health Effects 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010338159.XA CN111643517B (zh) | 2020-04-26 | 2020-04-26 | 桑葚多糖衍生物s-mfp-30在制备抗肿瘤药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010338159.XA CN111643517B (zh) | 2020-04-26 | 2020-04-26 | 桑葚多糖衍生物s-mfp-30在制备抗肿瘤药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111643517A CN111643517A (zh) | 2020-09-11 |
CN111643517B true CN111643517B (zh) | 2022-11-01 |
Family
ID=72342989
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010338159.XA Active CN111643517B (zh) | 2020-04-26 | 2020-04-26 | 桑葚多糖衍生物s-mfp-30在制备抗肿瘤药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111643517B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115611989B (zh) * | 2022-10-09 | 2023-08-01 | 武汉理工大学 | 机械活化淀粉衍生物抑制剂的优化制备方法及应用 |
CN115894728B (zh) * | 2022-10-11 | 2024-04-30 | 贵州师范大学 | 一种米邦塔仙人掌多糖map-2和制备方法及其应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU1692526A1 (ru) * | 1987-09-15 | 1991-11-23 | Институт Биоорганической Химии Ан Узсср | Способ получени концентрата дл безалкогольного тонизирующего напитка |
US20110218209A1 (en) * | 2010-03-06 | 2011-09-08 | Paul Daniel Yered | Nutrient delievry drug composition |
CN104211828B (zh) * | 2014-09-17 | 2016-08-24 | 上海交通大学 | 一种桑椹抗氧化多糖及其制备方法 |
CN105037575A (zh) * | 2015-07-22 | 2015-11-11 | 贵州师范大学 | 一种桑葚多糖的提取方法及其产品 |
-
2020
- 2020-04-26 CN CN202010338159.XA patent/CN111643517B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN111643517A (zh) | 2020-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108530551B (zh) | 贝母多糖的制备及在制备抗肿瘤药物中的应用 | |
CN103768534B (zh) | 一种具有抗肿瘤活性的中药组合物 | |
CN111643517B (zh) | 桑葚多糖衍生物s-mfp-30在制备抗肿瘤药物中的应用 | |
CN103204907B (zh) | 孔鳐软骨多肽类血管生成抑制因子及其制备方法和用途 | |
WO2016041258A1 (zh) | 一种竹荪多糖-锌螯合物的制备方法及其应用 | |
CN109276576A (zh) | 白肉灵芝多糖在制备抗肿瘤药物中的用途 | |
CN107854507B (zh) | 一种从艾叶中提取黄酮类成分的方法 | |
CN105148258A (zh) | 组合物及其应用,含有该组合物的制剂 | |
CN107245113B (zh) | 具有抗癌作用的玉米须多糖提取物及其制备方法 | |
CN110540603A (zh) | 知母多糖及其制备方法、鉴定方法和应用 | |
CN107722131B (zh) | 一种具有显著辅助抗肿瘤活性的全灵芝孢子粉精制多糖及其制备方法和应用 | |
CN111481564B (zh) | 桑葚多糖mfp-90-2在制备抗肿瘤药物中的应用 | |
CN105796587B (zh) | 竹茹多糖在免疫调节、抗肿瘤中的应用 | |
CN109602759B (zh) | 罗汉松实多糖的用途 | |
CN113667027A (zh) | 一种人参多糖组合物及其制备方法和应用 | |
CN110917288A (zh) | 一种具有抗肿瘤作用的中药组合物的包合制剂及其制备方法和应用 | |
CN113717296B (zh) | 一种杜仲酸性多糖、提取方法及其在制备抗结肠癌药物中的应用 | |
CN103191143B (zh) | 一种强心苷化合物的用途 | |
CN113024681B (zh) | 黄精半乳聚糖及其制备方法和应用 | |
CN112794923B (zh) | 川芎多糖及其制备方法、鉴定方法和应用 | |
CN112480281B (zh) | 一种短穗兔耳草多糖及制备抗肿瘤药物的用途 | |
CN114249846A (zh) | 一种酸性莼菜多糖及其分离纯化方法和应用 | |
CN109771452B (zh) | 虎奶菇提取物在制备治疗肿瘤药物中的应用 | |
CN104116024B (zh) | 肉苁蓉多糖在制备具有辅助抑制结肠癌功效的功能食品中的应用 | |
CN112592412B (zh) | 一种海茸岩藻聚糖硫酸酯及其在制备防治白细胞减少症的药物和功能性制品中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240117 Address after: No. 5-4 Xihu Street, Yuhong District, Shenyang City, Liaoning Province, 110000 (1-6-1) Patentee after: Shenyang Yufeng Life Technology Co.,Ltd. Address before: Room 1104, Building D, Ligang Galaxy Plaza, Intersection of Luzhou Avenue and Ziyun Road, Baohe District, Hefei City, Anhui Province, 230000 Patentee before: Hefei Jichu Information Technology Co.,Ltd. Effective date of registration: 20240117 Address after: Room 1104, Building D, Ligang Galaxy Plaza, Intersection of Luzhou Avenue and Ziyun Road, Baohe District, Hefei City, Anhui Province, 230000 Patentee after: Hefei Jichu Information Technology Co.,Ltd. Address before: 550001 No.116 Baoshan North Road, Yunyan District, Guiyang City, Guizhou Province Patentee before: Guizhou Normal University |
|
TR01 | Transfer of patent right |